Author Archives: Marta Figueiredo PhD

ZX008 Yields Significant, Long-Term Seizure Reduction in Dravet Patients, Phase 3 Data Reveal

Zogenix’s lead investigational compound ZX008 provided significant and long-term seizure reduction in Dravet syndrome patients, according to new clinical trial data. The company also revealed data from multiple studies assessing the psychological and socioeconomic impact of epileptic encephalopathies, including Dravet syndrome, in the United States and Europe. These findings were presented in multiple studies during…